A PYMNTS Company

Hypera’s Buscopan Deal Approved by Brazil Antitrust Body

By  |  July 30, 2020

Brazil antitrust regulator, known as CADE, unanimously approved in a session broadcast online the purchase by Hypera of Buscopan drug line from Boehringer Ingelheim GmbH for 1.3 billion reais (US$252.5 million), reported Bloomberg.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Deal was approved on condition that Hypera divests from the products that compete with Buscopan.

    Hypera, since the beginning of the operation, presented a proposal to sell its medicine Neocopan Composto to the company Uniao Quimica Farmaceutica Nacional to guarantee the approval of the deal.

    Sale of Neocopan Composto has been carried out and approved by CADE previously.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.